Literature DB >> 26763786

Von Hippel-Lindau disease: an evaluation of natural history and functional disability.

Alberto Feletti1, Mariagiulia Anglani1, Bruno Scarpa1, Francesca Schiavi1, Francesca Boaretto1, Stefania Zovato1, Elisa Taschin1, Mario Gardi1, Elisabetta Zanoletti1, Stefano Piermarocchi1, Alessandra Murgia1, Giacomo Pavesi1, Giuseppe Opocher1.   

Abstract

BACKGROUND: Although many studies have been published about specific lesions characterizing von Hippel-Lindau(VHL) disease, none have dealt with the natural history of the whole disease and the consequent disabilities. We aim to define the comprehensive natural history of VHL disease and to describe the functional disabilities and their impact upon patients' quality of life, thereby tailoring the follow-up schedule accordingly.
METHODS: We performed a prospective analysis on 128 VHL-affected patients beginning in 1996. For each affected organ, we defined intervals between the first and subsequent VHL-related manifestations and compared them with current VHL surveillance protocols. We looked for any association of the number of involved organs with age, sex, type of VHL gene mutation, and functional domain mutation. Ultimately, we assessed the organ-specific disabilities caused by VHL disease.
RESULTS: Hemangioblastomas show different patterns of progression depending on their location, whereas both renal cysts and carcinomas have similar progression rates. Surgery for pheochromocytoma and CNS hemangioblastoma is performed earlier than for pancreatic or renal cancer. The number of involved organs is associated with age but not with sex, type of VHL gene mutation, or functional domain mutation. A thorough analysis of functional disabilities showed that age is related to the first-appearing functional impairment, but it is not predictive of the final number of disabilities.
CONCLUSIONS: Our study defines the disease progression and provides a comprehensive view of the syndrome over time. We analyzed for the first time the functional disability of VHL patients, assessing the progression for each function.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  VHL; disability; follow-up; functional impairment; natural history

Mesh:

Year:  2016        PMID: 26763786      PMCID: PMC4896541          DOI: 10.1093/neuonc/nov313

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

1.  Molecular characterization of large deletions in the von Hippel-Lindau (VHL) gene by quantitative real-time PCR: the hypothesis of an alu-mediated mechanism underlying VHL gene rearrangements.

Authors:  Alberto Casarin; Maddalena Martella; Roberta Polli; Emanuela Leonardi; Laura Anesi; Alessandra Murgia
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau.

Authors:  P R Hammel; V Vilgrain; B Terris; A Penfornis; A Sauvanet; J M Correas; D Chauveau; A Balian; C Beigelman; D O'Toole; P Bernades; P Ruszniewski; S Richard
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

3.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

4.  Molecular analysis of two uncharacterized sequence variants of the VHL gene.

Authors:  Maddalena Martella; Leonardo Salviati; Alberto Casarin; Eva Trevisson; Giuseppe Opocher; Roberta Polli; David Gross; Alessandra Murgia
Journal:  J Hum Genet       Date:  2006-09-28       Impact factor: 3.172

Review 5.  Clinical management of Von Hippel-Lindau (VHL) disease.

Authors:  F J Hes; R B van der Luijt; C J Lips
Journal:  Neth J Med       Date:  2001-11       Impact factor: 1.422

Review 6.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

7.  Renal lesions in Von Hippel-Lindau disease: the benign, the malignant, the unknown.

Authors:  F Salomé; P Colombeau; V Fermeaux; P Cazaux; J P Dumas; P Pfeifer; J J Moreau; S Richard; F Labrousse
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

8.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease.

Authors:  Wai T Wong; Elvira Agrón; Hanna R Coleman; Tam Tran; George F Reed; Karl Csaky; Emily Y Chew
Journal:  Ophthalmology       Date:  2007-06-01       Impact factor: 12.079

View more
  12 in total

1.  Sporadic Hemangioblastoma Arising from the Infundibulum.

Authors:  Michael N Pakdaman; Matthew J Austin; Serguei Bannykh; Barry D Pressman
Journal:  J Radiol Case Rep       Date:  2017-05-31

2.  Von Hippel-Lindau disease with extramedullary and pancreatic involvement.

Authors:  Andrea Pantigozo-Rimachi; Giuliana Murillo-Díaz; Nilton Yhuri Carreazo; Victor Manuel Cucho Dávila
Journal:  Med J Armed Forces India       Date:  2020-05-07

3.  Intradural, extramedullary hemangioblastoma at the level of the conus medullaris: illustrative case.

Authors:  Lisa B E Shields; John E Harpring; Hilary A Highfield; Yi Ping Zhang; Christopher B Shields
Journal:  J Neurosurg Case Lessons       Date:  2021-04-26

4.  Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database.

Authors:  Xiangdong Yin; Hongzhou Duan; Zhiqiang Yi; Chunwei Li; Runchun Lu; Liang Li
Journal:  Front Oncol       Date:  2020-09-09       Impact factor: 6.244

5.  Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment.

Authors:  Liang Li; Zhiqiang Yi; Zhen Liu; Hongzhou Duan; Runchun Lu; Chunwei Li; Lei Li; Kan Gong
Journal:  Hered Cancer Clin Pract       Date:  2020-10-22       Impact factor: 2.857

Review 6.  Spinal hemangioblastoma: surgical procedures, outcomes and review of the literature.

Authors:  Huanyu Wang; Liping Zhang; Hong Wang; Yang Nan; Quanfeng Ma
Journal:  Acta Neurol Belg       Date:  2020-07-07       Impact factor: 2.396

7.  Overexpression of EGFR and TGFα in von Hippel-Lindau-Related Central Nervous System Hemangioblastomas.

Authors:  Zhen Liu; Liang Li; Zhiqiang Yi; Hongzhou Duan; Runchun Lu; Chunwei Li; Jingcheng Zhou; Kan Gong
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

8.  Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family.

Authors:  Aleksandra Gilis-Januszewska; Anna Bogusławska; Kornelia Hasse-Lazar; Beata Jurecka-Lubieniecka; Barbara Jarząb; Anna Sowa-Staszczak; Marta Opalińska; Magdalena Godlewska; Anna Grochowska; Anna Skalniak; Alicja Hubalewska-Dydejczyk
Journal:  Genes (Basel)       Date:  2021-03-31       Impact factor: 4.096

9.  Rehabilitation management in two siblings with Von Hippel-Lindau syndrome: A case series.

Authors:  Paraskevi Tsingeli; Maria Christina Papadatou; Despoina Psillaki; Vasileios Tragoulias; Nikolaos Groumas; Yannis Dionyssiotis
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-06-01       Impact factor: 2.041

Review 10.  A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors.

Authors:  Marina Tsoli; Kosmas Daskalakis; Eva Kassi; Gregory Kaltsas; Apostolos V Tsolakis
Journal:  Biology (Basel)       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.